Promoter holding
64.27%
TP
Therdose Pharma Private Limited - Due diligence report
A 360° intelligence report on Therdose Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signal…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹349
50% off
New user
Or enjoy up to 50% off with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Therdose Pharma — 360° Intelligence Report
Generated from MCA filings & public records68/100
Trust Score
Moderate
Therdose Pharma is assessed as Moderate with a Trust Score of 68/100. Therdose Pharma is an active private limited indian non-government company incorporated in 2003, operating in the Pharma sector. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and moderate financial risk profile.
Report generated on 08 Jul 2026 from the latest processed filings. Therdose Pharma Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
68/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
38/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
75/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
55/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 75/100 Low Risk
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (B).
Charges position: 1 open (11.58 cr) · 6 satisfied (24.13 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 4 | 48.0 cr |
| Indusind Bank Ltd. | 1 | 48.0 cr |
| Reliance Capital Ltd | 1 | 48.0 cr |
| Axis Bank Limited | 1 | 48.0 cr |
Compliance Score: 38/100 Caution Indicated
- Company status is Active as per MCA.
- Balance sheet slightly behind (Mar 2024).
- Flagged by authority: NCLT, EPFO.
- Litigation present in 4 court forum(s).
- 1 active GST registration(s).
Legal cases on record (4)
05
Director Intelligence
Stability score: 85/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| MEKA KESAVA SAMBASIVA RAO | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NARAYANA RAJU MANTANA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| ARVIND REDDY PANYALA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MAHINDRA DEV IMADABATHUNI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RAJA VAKULA DEVI IMADABATHUNI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| KUMAR MADASA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RATNA SEKHAR RAO IMADABATHUNI | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| MANTENA RAJU NARASA | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 8 directors on the board.
- No disqualified or deactivated DINs.
- 2 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Vance And Health Pharmaceuticals Private Limited
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 0 transfer(s)
Promoters hold a majority stake - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Vance And Health Pharmaceuticals Private Limited | Holding Company | 74.00% |
Key managerial personnel: MAHINDRA DEV IMADABATHUNI (Whole-time director) · KUMAR MADASA (CEO) · RATNA SEKHAR RAO IMADABATHUNI (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 55 · Distress 75
Growth signals & trust indicators
EPFO headcount growing - hiring signal.
Operating for 22+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Compliance score is weak (38/100).
1 open charge(s) registered - assets are encumbered.
4 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence58/100
Review suggested
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 1 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment64/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 11.58 cr already registered.
- Compliance gaps should be priced into terms.
Investor view64/100
Mixed indicators
Growth quality and scalability through an investor lens.
- 1 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events29 Sep 2024
Last AGM held
Annual general meeting
28 Sep 2024
Director ceased
NARAYANA RAJU MANTANA
15 Apr 2024
Director appointed
NARAYANA RAJU MANTANA (Director)
31 Mar 2024
Latest balance sheet
Filed with ROC
28 Sep 2023
Director ceased
RAJA VAKULA DEVI IMADABATHUNI
10 May 2023
Charge satisfied
Axis Bank Limited
08 Dec 2022
Charge created
Others - 11.58 cr
03 Oct 2022
Director appointed
RAJA VAKULA DEVI IMADABATHUNI (Director)
15 Jun 2022
Charge satisfied
Others
06 May 2022
Charge created
Axis Bank Limited - 25.68 Lakh
18 Apr 2022
Charge satisfied
Others
15 Feb 2022
Charge satisfied
Others
29 Nov 2021
Director ceased
MEKA KESAVA SAMBASIVA RAO
Director ceased
ARVIND REDDY PANYALA
Director ceased
MAHINDRA DEV IMADABATHUNI
10
Key Observations
Auto-generated from the data aboveRevenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Debt-to-equity stands at 24% - leverage worth monitoring.
Net worth is positive.
8 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Carries an external credit rating of B from Icra.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
1 overseas direct investment(s) (ODI) on record - international footprint.
| Company | CIN | Location |
|---|---|---|
| Omsav Pharma Research Private Limited | U24230MH2016PTC339817 | Mumbai, Maharashtra, India |
| Hylasco Bio-Technology | U01409TG2012PTC080696 | Hyderabad, Telangana, India |
| Ess Life Sciences India Private Limited | U74999DL2018PTC341681 | New Delhi, Delhi, India |
| Associated Electronics Research Foundation. | U00000DL1981NPL011318 | New Delhi, Delhi, India |
| Bugworks Research India Private Limited | U73100KA2014PTC073409 | Bangalore, Karnataka, India |
| Incozen | U24239TG2008PTC059967 | Hyderabad, Telangana, India |
| Energon Labs Private Limited | U73200TG2018PTC127126 | Hyderabad, Telangana, India |
| Netgear | U73100KA2012FTC064558 | Bangalore, Karnataka, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Therdose Pharma before audits and certifications: compliance score 38/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Therdose Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 75/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Mixed indicators. Growth score 55/100, margin trends, ownership structure and peer set for Therdose Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Review suggested. Trust score 68/100, distress signals and MSME payment-delay disclosures - know whether Therdose Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Therdose Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Therdose Pharma an active company?
Therdose Pharma has MCA status “Active” with a compliance score of 38/100 (Caution Indicated).
Is Therdose Pharma financially healthy?
Therdose Pharma has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.
Should I do business with Therdose Pharma?
Its overall Trust Score is 68/100 (Moderate). Vendor verdict: Review suggested. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Therdose Pharma?
The ultimate holding entity is Vance And Health Pharmaceuticals Private Limited. 8 active director(s) are on record.
Does Therdose Pharma have loans or charges against its assets?
1 open charge(s) are registered against its assets, and 6 earlier charge(s) stand satisfied.
Is Therdose Pharma up to date with its ROC filings?
Balance sheet slightly behind (Mar 2024). Overall compliance score: 38/100 (Caution Indicated).
Is it risky to lend to Therdose Pharma?
Its Credit Risk Score is 75/100 (Low Risk). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
